Schrodinger, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Technologies
    • Large Molecule
  • Digital Health
  • Contract Research Organization-CRO
See more in Biomedtracker

Latest on Schrodinger, Inc.

Scrip

Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sarepta Obtains Rights To Seven Arrowh

In Vivo

Schrödinger’s Akinsanya On Low-Risk Pipeline Growth And Platform Evolution

 
• By David Wild

Since its founding in 1990, New York-based Schrödinger has functioned as a platform company, identifying, validating, optimizing clinical candidates and doing preclinical development for other compani

Scrip

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie, Gilgamesh To Investigate Potent

Scrip

Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash

 
• By Mandy Jackson

Ajax Therapeutics, Inc. is going after an old target in myelofibrosis and other myeloproliferative neoplasms (MPNs) in a new way with its type II JAK2 inhibitor, AJ1-11095, which it will take into th